title: Consumption of palatable food decreases the anorectic effects of serotonergic, but not dopaminergic drugs in baboons.
abstract: We examined the effects of periodic access to a palatable, high sugar content food (candy) in 8 male baboons on the anorectic response to d-amphetamine, which increases dopamine, and dexfenfluramine, which increases serotonin. During candy access, up to 200 candies containing 75% of energy as sugar were available during the morning on Mondays, Wednesdays and Fridays; food pellets (19% of energy as sugar) were available in the afternoon and throughout the remaining days of the week. During candy access, baboons consumed a mean of 177 pieces of candy containing 696 kcal (2.91 MJ) in the morning compared to 44 food pellets and 150 kcal (0.63 MJ) in the morning on non-candy days. Food pellet intake was lower during candy access. Complete dose-response functions for the effects of the drugs on food pellet intake on days that candy was not available were determined before, during, and after the period of access to candy. Dexfenfluramine and amphetamine produced dose-dependent decreases in food pellet intake and increases in latency to eat food pellets before, during, and after candy access. During access to candy, the dose-response function for dexfenfluramine was shifted to the right indicating the development of tolerance, while that for amphetamine was shifted to the left indicating sensitization. Only the dose-response function for dexfenfluramine returned to baseline after candy access suggesting that the difference was specific to concurrent palatable food consumption. We hypothesize that tolerance to the effects of dexfenfluramine reflects a decrease in the satiating effect of serotonin release due to repeatedly eating large amounts of palatable food.
authors.affiliation: Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA. rwf2@columbia.edu
authors.forename: Richard W
authors.initials: RW
authors.lastname: Foltin
mesh_terms: D000661:Amphetamine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D000855:Anorexia / Q000139:chemically induced / Q000178:diet therapy*; D020372:Dexfenfluramine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D019422:Dietary Sucrose / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D018765:Dopamine Uptake Inhibitors / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004361:Drug Tolerance; D004435:Eating / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects; D008297:Male; D010215:Papio; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
chemical_list: D019422:Dietary Sucrose; D018765:Dopamine Uptake Inhibitors; D017366:Serotonin Receptor Agonists; D000661:Amphetamine; D020372:Dexfenfluramine